-
公开(公告)号：US20200085787A1
公开(公告)日：2020-03-19
申请号：US16617660
申请日：2018-06-01
IPC分类号： A61K31/397 , A61P25/28
摘要： An object of the present invention is to provide an excellent drug for preventing or treating spinocerebellar ataxia. 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or a salt thereof has an effect of suppressing brain atrophy, especially cerebellar atrophy, and is useful as an agent for preventing or treating spinocerebellar ataxia. Cerebellar atrophy observed in spinocerebellar ataxia can be prevented or treated by administering 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or a salt thereof.
-
12.发明申请公开(公告)号：US20200062789A1
公开(公告)日：2020-02-27
申请号：US16482003
申请日：2018-01-30
发明人： Muneo SHOJI , Yusuke NAGATO , Yuko SUZUMURA
IPC分类号： C07F9/09 , A61K31/661 , A61P31/04 , A61K9/19
摘要： An object of the present invention is to provide a compound or a salt thereof which shows strong antibacterial activity and has excellent solubility in water, and a lyophilized formulation, an LpxC inhibitor, and an antibacterial agent comprising the compound or a salt thereof. The present invention provides a compound represented by the Formula [1] or a salt thereof: wherein R1 represents a hydrogen atom or the like, R2 represents a hydrogen atom or the like, R3 represents a hydrogen atom or the like, R4 represents a hydrogen atom or the like, and n represents 0 or 1.
-
公开(公告)号：US10174001B2
公开(公告)日：2019-01-08
申请号：US15755281
申请日：2016-08-30
发明人： Yusuke Okubo , Tadashi Tanaka
IPC分类号： C07D401/12
摘要： Crystals of 5-cyclopropyl-2-((1-(3-fluorobenzyl)-1H-indol-5-yl)amino)nicotinic acid having diffraction peaks at diffraction angles (2θ) of 12.2±0.2, 17.2±0.2, 19.4±0.2, 24.1±0.2, and 27.1±0.2° or diffraction angles (2θ) of 12.9±0.2, 15.5±0.2, 21.2±0.2, 21.7±0.2, and 25.9±0.2° in powder x-ray diffraction have excellent stability, are easy to handle, and are useful as a drug substance of pharmaceuticals to be used in treatments such as the prevention or treatment of diseases involving keratinocyte hyperproliferation.
-
公开(公告)号：US20240245679A1
公开(公告)日：2024-07-25
申请号：US18559873
申请日：2022-05-12
发明人： Takashi KOMENO , Yousuke FURUTA
IPC分类号： A61K31/4965 , A61P31/14
CPC分类号： A61K31/4965 , A61P31/14
摘要： This agent for treating coronavirus infectious diseases caused by mutant viruses of SARS-COV-2 contains, as an active ingredient, 6-fluoro-3-hydroxy-2-pyrazinecarboxamide or a salt thereof.
-
公开(公告)号：US20240112476A1
公开(公告)日：2024-04-04
申请号：US18473551
申请日：2023-09-25
发明人： Shinji HANEDA
CPC分类号： G06V20/60 , G06F16/156 , G06V10/56 , G06V10/75 , G06V10/764 , G06V10/77 , G06V10/945
摘要： One or more processors calculate a first score value indicating likelihood of being a type of the identification target drug with respect to each of a plurality of types of drugs from the image by using a first trained model trained to identify a type of an identification target drug from an image obtained by capturing the identification target drug, identify one or more appearance attributes of the identification target drug from the image, acquire information on drug types matching the attributes of the identification target drug from the drug master file including information on one or more appearance attributes regarding each of a plurality of types of drugs identifiable by the first trained model, calculate a second score value by using the first score value and a value being set for the attribute; and present a candidate for the type of the identification target drug based on second score value.
-
公开(公告)号：US20230368552A1
公开(公告)日：2023-11-16
申请号：US18358204
申请日：2023-07-25
发明人： Shinji HANEDA , Masanobu Takashima
IPC分类号： G06V30/14 , G06V30/19 , G06V30/146 , G06V30/18 , G06F16/903 , G16H70/40
CPC分类号： G06V30/1448 , G06V30/19173 , G06V30/146 , G06V30/19013 , G06V30/1434 , G06V30/1801 , G06V30/19147 , G06F16/90344 , G16H70/40
摘要： A region of a drug to be identified is detected from a captured image generated by imaging the drug to be identified that is imparted with engraved mark and/or print. The region of the drug to be identified in the captured image is processed to acquire an engraved mark and print extraction image that is an extracted image of the engraved mark and/or print of the drug to be identified. The engraved mark and print extraction image is input, and a drug type of the drug to be identified is inferred to acquire a candidate of the drug type of the drug to be identified.
-
公开(公告)号：US20230210848A1
公开(公告)日：2023-07-06
申请号：US17997422
申请日：2021-04-27
发明人： Takashi KOMENO , Nozomi YAMASHITA
IPC分类号： A61K31/4965 , A61K45/06 , A61P31/14 , A61K31/706
CPC分类号： A61K31/4965 , A61K45/06 , A61P31/14 , A61K31/706
摘要： An object of the present invention is to provide a novel combination of substances showing effects against coronavirus. The present invention provides a therapeutic agent for coronavirus infection comprising a combination of a pyrazine derivative or a salt thereof and another therapeutic agent for coronavirus infection.
-
公开(公告)号：US20230127703A1
公开(公告)日：2023-04-27
申请号：US17907722
申请日：2021-03-26
发明人： Tsutomu SAKURAI
IPC分类号： A61K31/4965 , A61P31/14
摘要： Coronavirus infection can be treated by administering a pharmaceutical composition comprising 6-fluoro-3-hydroxy-2-pyrazinecarboxamide or a salt thereof as an active ingredient to coronavirus infection patient with non-serious pneumonia.
-
公开(公告)号：US11501866B2
公开(公告)日：2022-11-15
申请号：US17020090
申请日：2020-09-14
发明人： Kazuchika Iwami , Koji Yokouchi
摘要： In the present invention, an image of a verification target medicine disposed on an arrangement unit is captured, prescription condition information indicating a prescription condition is acquired, an external force application unit is caused to execute an external force applying operation of applying an external force to the medicine disposed on the arrangement unit to move the medicine when an operation execution condition is satisfied, wherein the operation execution condition includes at least one of: a first operation execution condition that the number of the verification target medicines appearing in the image differs from the quantity of the medicines specified from the prescription condition information; and a second operation execution condition that a shape of the verification target medicine appearing in the image differs from a shape corresponding to a type of the medicine specified from the prescription condition information.
-
20.发明授权公开(公告)号：US11423246B2
公开(公告)日：2022-08-23
申请号：US16788001
申请日：2020-02-11
发明人： Koji Yokouchi
IPC分类号： H04N7/18 , G06K9/62 , G06T7/586 , G06T7/13 , G16H30/40 , G16H20/13 , G06T5/00 , G06T5/50 , H04N5/235 , G06V10/141 , G06V10/145
摘要： A medicine inspection assistance device, an image processing device and an image processing method are provided that appropriately recognize identification information irrespective of whether the identification information is an engraved mark or a printed character. The image processing device that obtains a plurality of taken images of a medicine, performs a process of enhancing an engraved mark portion of the medicine based on at least one taken image among the taken images and generates a first enhanced image, performs a process of enhancing a printed character portion of the medicine based on at least one taken image among the taken images and generates a second enhanced image, collates an integrated image obtained by integrating the first enhanced image and the second enhanced image with each other, with a master image, and determines whether the medicine to be dispensed and the dispensed medicine are identical to each other or not.
-
-
-
-
-
-
-
-
-
搜索结果
90 条记录 (耗时 0.025 秒)
